We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Amneal Pharmaceuticals Inc (AMRX) USD0.01 A

Sell:$4.26 Buy:$4.27 Change: $0.02 (0.47%)
Market closed |  Prices as at close on 29 November 2021 | Switch to live prices |
Change: $0.02 (0.47%)
Market closed |  Prices as at close on 29 November 2021 | Switch to live prices |
Change: $0.02 (0.47%)
Market closed |  Prices as at close on 29 November 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Amneal Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the developing, manufacturing, marketing and distributing high-value generic and branded specialty pharmaceutical products across a broad array of dosage forms and therapeutic areas. It operates in three segments, which include Generics, Specialty and AvKARE. The Generics segment provides prescription pharmaceutical products. The Specialty Pharma is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system (CNS) disorders. AvKARE segment provides pharmaceuticals, medical and surgical products and services to governmental agencies. Its other pipeline includes 505(b)(2) drugs and complex generics.

Contact details

400 Crossing Blvd Fl 3
United States
+1 (908) 9473120

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.28 billion
Shares in issue:
301.49 million
New York Stock Exchange
United States
US dollar

Key personnel

  • Chirag Patel
    President, Co-Chief Executive Officer, Co-Founder, Director
  • Chintu Patel
    Co-Chief Executive Officer, Co-Founder, Director
  • Anastasios Konidaris
    Chief Financial Officer, Executive Vice President
  • Nikita Shah
    Chief Human Resource Officer, Executive Vice President, Strategic Planning Officer
  • Andrew Boyer
    Executive Vice President, Chief Commercial Officer - Generics
  • Joseph Todisco
    Executive Vice President, Chief Commercial Officer - Specialty
  • Stephen Manzano
    Senior Vice President, General Counsel and Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.